


REVION HEALTH CARE (UK) LIMITED

U0000024/1



Armour Pharmaceutical
Company Limited

INTER OFFICE MEMORANDUM



BERK
Pharmaceuticals Ltd.

TO : P. Harris

DATE: 6th March 1986

FROM : C.R. Bishop

REF: CRB/BAK

SUBJECT : U.K. HAEMOPHILIA CENTRE DIRECTORS MEETING - ST. THOMAS' HOSPITAL
MONDAY 17TH MARCH

COPIES TO :

K.W. Fitch
J.D. Michelmore
Sheppard
R.B. Christie
L. Lucas
Master
Day
File

Following the above, at which is anticipated most, if not all, the U.K. Directors will be present, a Meeting of the Haemostasis Club will be held, the topic being "Blood Products".

Dr. Zuckerman or Dr. Williams, Consultant Hepatologists from Kings will be invited, as will Dr. P. Kernoff from The Royal Free to talk on Clinical Trials, Eric Preston from Sheffield to talk on Liver Disease, Charles Rizza from Oxford to talk on the NHS 8Y experience and Dr. Lane from The Blood Products Laboratory at Elstree to talk on U.K. self-sufficiency.

The Chairman will be Geoff Savidge from St. Thomas' who, together with Dr.'s Kernoff and Preston, are the leading advocates for the "safer wet heat treated" Alpha factor VIII (Profilate).

I suspect that this could be a very cleverly connived Meeting at the instigation of either these three Clinicians or Alpha themselves to convert all Directors to a product/s which can be shown to have a better track record with regard to the elimination of NANB hepatitis. It is also, obviously, an attempt to expose the potential mid/long term problems associated with liver disease in haemophilia, as initially advocated by Hay et.al. in articles in The Lancet during 1985.

The attached letter in The Lancet, February 8th 1986, page 322, from Professor Kl. Schimpf from Heidelberg, further adds fuel to the current argument and from which we can glean little comfort in the light of our previous experiences with the Factorate Intermediate product.

However, I know you will appreciate the vital significance and importance of this Meeting to haemophiliacs, clinicians and the factor VIII producers alike and, in your absence, Robert has agreed to accompany me. I also strongly urge, in most forceful terms, that Bill Terry or Mike Hrinda, or somebody from the U.S. attends this Meeting to hear the story "from the horses mouth" and particularly as it relates to our market position in the U.K. Geoff Savidge has kindly agreed to put questions on our behalf to the Panel and this will be an ideal opportunity to obtain an authoritative opinion from the leaders in the field on any subjects which are of particular interest to us and I would suggest that one or two very carefully constructed questions be discussed between us and put to Geoff in advance.

REV 48

ARMOUR002830

ARMO0000505_001_0001

Perhaps the U.S. would like to make some input in this direction as well. I am particularly thinking of the Panels views with regard to purity of product, in terms of foreign protein, other immunoglobulins etc. and their impact both on the immune system and liver disease.

This is perhaps the most vital Meeting affecting our plasma business which has yet been held and I would strongly urge that everything be done to obtain the maximum scientific data that we can from this opportunity.

Perhaps we can discuss this in more detail, possibly on Friday before you take a well earned rest.



GRO-C

C.R. Bishop.